Lantern Pharma (LTRN) Other Non Operating Income (2021 - 2026)
Lantern Pharma's (LTRN) quarterly Other Non Operating Income came in at $33916.0 in Q1 2026, down 61.22% YoY from $87459.0 in Q1 2025, and down 39.51% on a QoQ basis from $56070.0 in Q4 2025.
Lantern Pharma (LTRN) Other Non Operating Income (2021 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 6 years of Other Non Operating Income data on file, last reported at $33916.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 61.22% year-over-year to $33916.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $367582.0 (down 46.73% YoY) and the FY2025 annual result came in at $421125.0, down 39.22% from the prior year.
- Other Non Operating Income slipped to $33916.0 in Q1 2026, from $56070.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $482527.0 in Q3 2024 to a low of -$171648.0 in Q3 2022.
- A 5-year average of $133353.5 and a median of $90241.0 in 2024 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 1216.22% in 2022, down 1070.91% in 2022.
- Tracing LTRN's Other Non Operating Income over 5 years: stood at $370489.0 in 2022, then increased by 14.46% to $424074.0 in 2023, then tumbled by 133.06% to -$140194.0 in 2024, then soared by 139.99% to $56070.0 in 2025, then tumbled by 39.51% to $33916.0 in 2026.
- The last three Other Non Operating Income figures came in at $33916.0 (Q1 2026), $56070.0 (Q4 2025), and $71456.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lantern Pharma | 26.05 Mn | 26.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33,916.00 |
| Dec 31, 2025 | 56,070.00 |
| Sep 30, 2025 | 71,456.00 |
| Jun 30, 2025 | 206,140.00 |
| Mar 31, 2025 | 87,459.00 |
| Dec 31, 2024 | -140,194.00 |
| Sep 30, 2024 | 482,527.00 |
| Jun 30, 2024 | 260,295.00 |
| Mar 31, 2024 | 90,241.00 |
| Dec 31, 2023 | 424,074.00 |
| Sep 30, 2023 | 115,777.00 |
| Jun 30, 2023 | 326,076.00 |
| Mar 31, 2023 | 284,721.00 |
| Dec 31, 2022 | 370,489.00 |
| Sep 30, 2022 | -171,648.00 |
| Jun 30, 2022 | -152,591.00 |
| Mar 31, 2022 | -77,798.00 |
| Dec 31, 2021 | 28,148.00 |
| Sep 30, 2021 | 17,679.00 |
| Jun 30, 2021 | 114,723.00 |